



-92-

## ABSTRACT

5 The present invention describes methods for inhibiting angiogenesis in tissues using vitronectin  $\alpha_v\beta_5$  antagonists. The  $\alpha_v\beta_5$ -mediated angiogenesis is correlated with exposure to cytokines including vascular endothelial growth factor, transforming growth  
10 factor- $\alpha$  and epidermal growth factor. Inhibition of  $\alpha_v\beta_5$ -mediated angiogenesis is particularly preferred in vascular endothelial ocular neovascular diseases, in tumor growth and in inflammatory conditions, using therapeutic compositions containing  $\alpha_v\beta_5$  antagonists.